lactose has been researched along with fluticasone in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bye, A; Daley-Yates, PT; Falcoz, C; McDowall, JE; Oliver, R; Ventresca, P | 1 |
| Hickey, AJ; Louey, MD; Van Oort, M | 1 |
| Dawson, ML; Ferrie, AR; Harris, H; Hooton, JC; Jones, MD; King, GS; Mathoulin, CA; Nichol, K; Price, R; Shur, J; Smith, TL | 1 |
| Marriott, C; Martin, GP; Murnane, D | 1 |
| Donovan, R; Elder, D; Freney, E; New, A; Prime, D; Zomer, S | 1 |
| Fujita, K; Ise, Y; Ishii-Nozawa, R; Katayama, S; Takeuchi, K | 1 |
| Hickey, AJ; Langridge, J; Mansour, HM; McLean, R; Mulder, T; Xu, Z | 1 |
| Flament, MP; Le, VN; Robins, E | 2 |
| Marriott, C; Martin, GP; Taki, M; Zeng, XM | 1 |
| Bierend, H; Flament, MP; Le, VN; Robins, E; Steckel, H | 1 |
| Flament, MP; Hoang Thi, TH; Le, VN; Robins, E | 2 |
| de Boer, HA; Frijlink, HW; Grasmeijer, F; Hagedoorn, P | 1 |
| Collins, E; Forbes, B; Hammond, RB; Jaffari, S; Martin, GP; Murnane, D; Pencheva, K; Pickering, J; Ramachandran, V; Roberts, KJ; Soufian, M | 1 |
| Depasquale, R; Lee, SL; Price, R; Saluja, B; Shur, J | 1 |
| Abdul, S; Darshana, H; Gaikwad, RV; Jain, RR; Menon, MD; Singh, DJ; Soni, PS | 1 |
| Lee, S; Price, R; Saluja, B; Shur, J; Tibbatts, J | 1 |
| Hoe, S; Lechuga-Ballesteros, D; Vehring, R; Wang, H; Williams, L | 1 |
| Elsayed, MM; Molokhia, AM; Shalash, AO | 1 |
| Elsayed, MMA; Shalash, AO | 1 |
| Choi, HG; Jin, SG; Kim, DW; Kim, JH; Kim, JO; Kim, KS; Oh, KT; Woo, JS; Yong, CS; Youn, YS | 1 |
| Elsayed, MMA; Khalafallah, NM; Molokhia, AM; Shalash, AO | 1 |
| Chan, HK; Holl, MMB; Ke, WR; Khanal, D; Kim, J; Zhang, J | 1 |
| Guan, J; He, X; Li, J; Ma, S; Mao, S; Sun, Y; Zhang, X | 1 |
1 trial(s) available for lactose and fluticasone
| Article | Year |
|---|---|
Bioavailability of orally administered micronised fluticasone propionate.
Topics: Administration, Oral; Adult; Androstadienes; Anti-Asthmatic Agents; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; Fluticasone; Humans; Hydrocortisone; Lactose; Male | 2000 |
24 other study(ies) available for lactose and fluticasone
| Article | Year |
|---|---|
Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.
Topics: Administration, Inhalation; Aerosols; Androstadienes; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Excipients; Fluticasone; Lactose; Microscopy, Electron, Scanning; Particle Size; Powders; Temperature | 2004 |
An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
Topics: Adhesiveness; Administration, Inhalation; Albuterol; Androstadienes; Anti-Allergic Agents; Capsules; Chemistry, Pharmaceutical; Crystallization; Drug Carriers; Excipients; Fluticasone; Lactose; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Particle Size; Powders; Salmeterol Xinafoate; X-Ray Diffraction | 2008 |
Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Albuterol; Androstadienes; Bronchodilator Agents; Chemistry, Pharmaceutical; Crystallization; Drug Compounding; Fluticasone; Lactose; Nebulizers and Vaporizers; Particle Size; Polyethylene Glycols; Powders; Salmeterol Xinafoate | 2009 |
Detection and assessment of co-association in inhalable drug particles using aerosol time-of-flight mass spectrometry.
Topics: Administration, Inhalation; Aerosols; Albuterol; Androstadienes; Bronchodilator Agents; Drug Combinations; Fluticasone; Fluticasone-Salmeterol Drug Combination; Humans; Lactose; Mass Spectrometry; Metered Dose Inhalers; Multivariate Analysis; Nebulizers and Vaporizers; Particle Size; Principal Component Analysis; Salmeterol Xinafoate | 2008 |
[Survey of the drugs remaining in the diskhaler and investigation of cleaning of fluticasone propionate].
Topics: Adhesiveness; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Androstadienes; Female; Fluticasone; Humans; Lactose; Male; Metered Dose Inhalers; Middle Aged; Surveys and Questionnaires; Young Adult | 2009 |
Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
Topics: Administration, Inhalation; Aerosols; Algorithms; Androstadienes; Bronchodilator Agents; Calorimetry, Differential Scanning; Drug Carriers; Drug Compounding; Fluticasone; Ipratropium; Lactose; Lasers; Microscopy, Electron, Scanning; Particle Size; Powders; X-Ray Diffraction | 2010 |
Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Topics: Administration, Inhalation; Air; Androstadienes; Bronchodilator Agents; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Fluticasone; Lactose; Models, Theoretical; Particle Size; Permeability; Powders; Terbutaline | 2010 |
The production of 'aerodynamically equivalent' drug and excipient inhalable powders using a novel fractionation technique.
Topics: Administration, Inhalation; Aerosols; Albuterol; Androstadienes; Anti-Allergic Agents; Bronchodilator Agents; Chemical Fractionation; Crystallization; Drug Compounding; Excipients; Fluticasone; Humans; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Salmeterol Xinafoate | 2011 |
Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Topics: Adhesiveness; Adsorption; Aerosols; Androstadienes; Bronchodilator Agents; Chemistry, Pharmaceutical; Chromatography, Gas; Drug Carriers; Drug Compounding; Fluticasone; Lactose; Particle Size; Powders; Technology, Pharmaceutical; Terbutaline | 2012 |
Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Topics: Administration, Inhalation; Aerosols; Androstadienes; Chemistry, Pharmaceutical; Drug Carriers; Dry Powder Inhalers; Fluticasone; Lactose; Particle Size; Powders; Silica Gel | 2012 |
In vitro evaluation of powders for inhalation: the effect of drug concentration on particle detachment.
Topics: Adhesiveness; Androstadienes; Bronchodilator Agents; Chemistry, Pharmaceutical; Drug Carriers; Dry Powder Inhalers; Ethanolamines; Fluticasone; Formoterol Fumarate; Lactose; Powders | 2012 |
Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
Topics: Adhesiveness; Administration, Inhalation; Aerosols; Androstadienes; Bronchodilator Agents; Chemistry, Pharmaceutical; Drug Carriers; Drug Storage; Dry Powder Inhalers; Fluticasone; Humidity; Lactose; Particle Size; Powders; Technology, Pharmaceutical; Time Factors; Water | 2012 |
Mixing time effects on the dispersion performance of adhesive mixtures for inhalation.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Chemistry, Pharmaceutical; Drug Carriers; Fluticasone; Lactose; Lasers; Microscopy, Electron, Scanning; Particle Size; Salmeterol Xinafoate; Solubility; Time Factors; X-Ray Diffraction | 2013 |
Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
Topics: Administration, Inhalation; Aerosols; Albuterol; Androstadienes; Budesonide; Chemistry, Pharmaceutical; Chromatography, Gas; Computer Simulation; Crystallization; Drug Delivery Systems; Excipients; Fluticasone; Hydrogen Bonding; Lactose; Lasers; Models, Theoretical; Particle Size; Powders; Static Electricity; Surface Properties | 2015 |
The influence of secondary processing on the structural relaxation dynamics of fluticasone propionate.
Topics: Administration, Inhalation; Bronchodilator Agents; Chemistry, Pharmaceutical; Dry Powder Inhalers; Fluticasone; Lactose; Particle Size; Powders; Salmeterol Xinafoate; Surface Properties | 2015 |
Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Topics: Aerosols; Bronchodilator Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Carriers; Drug Delivery Systems; Drug Stability; Dry Powder Inhalers; Equipment Design; Excipients; Fluticasone; Humidity; Lactose; Microscopy, Atomic Force; Powder Diffraction; Powders; Rheology; Surface Properties; Temperature; Time Factors | 2015 |
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.
Topics: Administration, Inhalation; Chemistry, Pharmaceutical; Dry Powder Inhalers; Equipment Design; Excipients; Fluticasone; Hydrodynamics; In Vitro Techniques; Lactose; Particle Size; Surface Properties | 2015 |
Quantitative Macro-Raman Spectroscopy on Microparticle-Based Pharmaceutical Dosage Forms.
Topics: Bronchodilator Agents; Fluticasone; Fluticasone-Salmeterol Drug Combination; Lactose; Particle Size; Powders; Salmeterol Xinafoate; Spectrum Analysis, Raman | 2015 |
Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adhesiveness; Administration, Inhalation; beta-Cyclodextrins; Carbohydrates; Drug Carriers; Drug Compounding; Dry Powder Inhalers; Excipients; Fluticasone; Glucose; Lactose; Mannitol; Models, Chemical; Particle Size; Porosity; Powders; Sucrose; Surface Properties; Tensile Strength; Xylitol | 2015 |
A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
Topics: Administration, Inhalation; Chemistry, Pharmaceutical; Drug Carriers; Dry Powder Inhalers; Excipients; Fluticasone; Lactose; Particle Size; Powders | 2017 |
Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Topics: Administration, Inhalation; Aerosols; Capsules; Chemistry, Pharmaceutical; Dry Powder Inhalers; Fluticasone; Lactose; Particle Size; Powders; Salmeterol Xinafoate | 2018 |
The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
Topics: Administration, Inhalation; Aerosols; Drug Carriers; Dry Powder Inhalers; Fluticasone; Lactose; Particle Size; Permeability; Porosity; Powders | 2018 |
Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
Topics: Administration, Inhalation; Aerosols; Chemistry, Pharmaceutical; Dry Powder Inhalers; Excipients; Fluticasone; Lactose; Particle Size; Powders; Respiratory Aerosols and Droplets; Salmeterol Xinafoate; Spectrum Analysis | 2023 |
Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
Topics: Administration, Inhalation; Aerosols; Drug Carriers; Dry Powder Inhalers; Fluticasone; Lactose; Particle Size; Powders | 2023 |